Literature DB >> 20656830

Multiparametric imaging of tumor response to therapy.

Anwar R Padhani1, Kenneth A Miles.   

Abstract

There is an increasing opportunity to perform multifunctional imaging at a variety of organ sites with relatively short examination times. Each technique yields quantitative parameters that reflect specific aspects of the underlying tumor or tissue biology. Many biomarkers have emerged that provide unique information on tumor behavior, including response to treatment. The multiparametric approach combines the information from different functional imaging techniques; this goes beyond what can be achieved by using any single functional technique, thus allowing an improved understanding of biologic processes and of responses to therapeutic interventions. Multiparametric imaging has many potential clinical roles; it is useful for pharmaceutical drug development and for predicting therapeutic efficacy.

Entities:  

Mesh:

Year:  2010        PMID: 20656830     DOI: 10.1148/radiol.10091760

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  77 in total

1.  Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.

Authors:  Xia Li; Richard G Abramson; Lori R Arlinghaus; Hakmook Kang; Anuradha Bapsi Chakravarthy; Vandana G Abramson; Jaime Farley; Ingrid A Mayer; Mark C Kelley; Ingrid M Meszoely; Julie Means-Powell; Ana M Grau; Melinda Sanders; Thomas E Yankeelov
Journal:  Invest Radiol       Date:  2015-04       Impact factor: 6.016

Review 2.  Imaging of lung cancer in the era of molecular medicine.

Authors:  Mizuki Nishino; David M Jackman; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson; Annick D Van den Abbeele
Journal:  Acad Radiol       Date:  2011-01-28       Impact factor: 3.173

Review 3.  Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.

Authors:  James P B O'Connor; Alan Jackson; Geoff J M Parker; Caleb Roberts; Gordon C Jayson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-14       Impact factor: 66.675

4.  Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.

Authors:  Louisa Bokacheva; Khushali Kotedia; Megan Reese; Sally-Ann Ricketts; Jane Halliday; Carl H Le; Jason A Koutcher; Sean Carlin
Journal:  NMR Biomed       Date:  2012-07-08       Impact factor: 4.044

Review 5.  Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts.

Authors:  Hee Kang; Ho Yun Lee; Kyung Soo Lee; Jae-Hun Kim
Journal:  Korean J Radiol       Date:  2012-06-18       Impact factor: 3.500

6.  Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer.

Authors:  Huaijun Wang; Guy Marchal; Yicheng Ni
Journal:  World J Radiol       Date:  2011-01-28

7.  Imaging-based observational databases for clinical problem solving: the role of informatics.

Authors:  Alex A T Bui; William Hsu; Corey Arnold; Suzie El-Saden; Denise R Aberle; Ricky K Taira
Journal:  J Am Med Inform Assoc       Date:  2013-06-17       Impact factor: 4.497

8.  Integrated ¹⁸F-FDG PET/perfusion CT for the monitoring of neoadjuvant chemoradiotherapy in rectal carcinoma: correlation with histopathology.

Authors:  Michael A Fischer; Bart Vrugt; Hatem Alkadhi; Dieter Hahnloser; Thomas F Hany; Patrick Veit-Haibach
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-24       Impact factor: 9.236

Review 9.  [Oncological imaging for therapy response assessment].

Authors:  J Stattaus
Journal:  Radiologe       Date:  2014-01       Impact factor: 0.635

10.  A comparison of radial keyhole strategies for high spatial and temporal resolution 4D contrast-enhanced MRI in small animal tumor models.

Authors:  Ergys Subashi; Everett J Moding; Gary P Cofer; James R MacFall; David G Kirsch; Yi Qi; G Allan Johnson
Journal:  Med Phys       Date:  2013-02       Impact factor: 4.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.